Prostate cancer screening markers

Jemal, 2007, Cancer statistics, 2007, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43 The American Cancer Society. Cancer Facts & Figures, 2007. pp. 17–19. available at http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Riegman, 1989, The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19, FEBS Lett, 247, 123, 10.1016/0014-5793(89)81253-0 Boccon-Gibod, 2001, Rising PSA with negative biopsy, Eur Urol, 40, 3, 10.1159/000049878 Brawer, 2000, Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer, J Urol, 163, 1476, 10.1016/S0022-5347(05)67646-X Catalona, 1991, Measurement of prostate specific antigen in serum as a screening test for prostate cancer, N Eng J Med, 324, 1156, 10.1056/NEJM199104253241702 Bretton, 1994, Prostate specific antigen and digital rectal examination in screening for prostate cancer: a community based study, South Med J, 87, 720, 10.1097/00007611-199407000-00009 Catalona, 1993, Detection of organ confined prostate cancer is increased through prostate specific antigen based screening, JAMA, 270, 948, 10.1001/jama.1993.03510080052031 Catalona, 1997, Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements, JAMA, 277, 1452, 10.1001/jama.1997.03540420048028 Catalona, 1999, Use of percentage of free prostate specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model, Urology, 54, 220, 10.1016/S0090-4295(99)00185-5 Djavan, 1999, PSA, PSA density, PSA density of transitional zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0ng/ml, Urology, 54, 517, 10.1016/S0090-4295(99)00153-3 Babaian, 2000, Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0ng/ml, Urology, 56, 1000, 10.1016/S0090-4295(00)00830-X Catalona, 1998, Use of percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, JAMA, 279, 1542, 10.1001/jama.279.19.1542 Djavan, 1998, Prostate specific antigen density of the transitional zone for early detection of prostate cancer, J Urol, 160, 411, 10.1016/S0022-5347(01)62911-2 Djavan, 2000, Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 patients, J Urol, 163, 1144, 10.1016/S0022-5347(05)67711-7 Piironen, 1996, In vitro stability of free prostate specific antigen (PSA) and prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin in blood samples, Urology, 48, 81, 10.1016/S0090-4295(96)00616-4 Babaian, 1990, Prostate specific antigen and prostate gland volume: correlation and clinical application, J Clin Lab Anal, 4, 135, 10.1002/jcla.1860040212 Benson, 1992, The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen, J Urol, 147, 817, 10.1016/S0022-5347(17)37394-9 Morote, 1997, J Urol, 158, 502, 10.1016/S0022-5347(01)64517-8 Kuriyama, 1999, Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels, Jpn J Clin Oncol, 29, 617, 10.1093/jjco/29.12.617 Reissigl, 1997, Prostate cancer screening in the county of Tyrol, Austria: experience and results, Cancer, 80, 1818, 10.1002/(SICI)1097-0142(19971101)80:9<1818::AID-CNCR21>3.0.CO;2-7 Borer, 1998, Age specific prostate specific antigen reference ranges: population specific, J Urol, 159, 444, 10.1016/S0022-5347(01)63945-4 Schmid, 1993, Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume, Cancer, 71, 2031, 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q Carter, 1992, Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease, Cancer Res, 52, 3323 Ornstein, 1997, Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers, J Urol, 157, 2179, 10.1016/S0022-5347(01)64708-6 Nixon, 1997, Day to day changes in free and total PSA: significance of biological variation, Prostate Cancer Prostatic Dis, 1, 90, 10.1038/sj.pcan.4500212 Carter, 2006, Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability, J Natl Cancer Inst, 98, 1521, 10.1093/jnci/djj410 Loeb, 2007, Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy, Urology, 69, 108, 10.1016/j.urology.2006.09.040 Berger, 2007, Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer, Urology, 69, 134, 10.1016/j.urology.2006.09.018 Porter, 1994, The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy, J Urol, 264, 239A Nixon, 1998, Comparison of three investigational assays for the free form of prostate specific antigen, J Urol, 160, 420, 10.1016/S0022-5347(01)62913-6 Brawer, 1998, Measurement of complexed PSA improves the specificity for early detection of prostate cancer, Urology, 52, 372, 10.1016/S0090-4295(98)00241-6 Okegawa, 2000, Comparison of two investigational assays for the complexed prostate specific antigen in total prostate specific antigen between 4.0 and 10.0ng/ml, Urology, 55, 700, 10.1016/S0090-4295(99)00589-0 Mitchell, 2001, A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer, J Urol, 165, 49, 10.1016/S0022-5347(05)66346-X Miller, 2001, Contemporary use of complexed PSA and calculated per cent free PSA for early detection of prostate cancer: impact of changing demographics, Urology, 57, 1105, 10.1016/S0090-4295(01)00953-0 Djavan, 2002, Urology, 60, 4, 10.1016/S0090-4295(02)01896-4 Maeda, 1999, Complexed prostate specific antigen and its volume indexes in the detection of prostate cancer, Urology, 54, 225, 10.1016/S0090-4295(99)00149-1 Partin, 2003, Complexed prostate specific antigen improves the specificity for prostate cancer detection: results of a prospective multicenter clinical trial, J Urol, 170, 1787, 10.1097/01.ju.0000092695.55705.dd Horninger, 2002, Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter, Urology, 60, 31, 10.1016/S0090-4295(02)01693-X Figueroa, 1998, Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer, J Urol, 159, 1379, 10.1016/S0022-5347(01)63620-6 Thrasher, 1996, Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations, J Urol, 155, 999, 10.1016/S0022-5347(01)66367-5 Chan, 1998, Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study, Science, 279, 563, 10.1126/science.279.5350.563 Stattin, 2000, Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study, J Natl Cancer Inst, 92, 1910, 10.1093/jnci/92.23.1910 Partin, 1999, Use of human glandular kallikrein 2 for detection of prostate cancer: preliminary analysis, Urology, 54, 839, 10.1016/S0090-4295(99)00270-8 Darson, 1999, Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases, Urology, 53, 939, 10.1016/S0090-4295(98)00637-2 Becker, 2000, Clinical value of human glandular kallikrein 2 and free and total prostate specific antigen in serum from a population of men with prostate specific antigen levels 3ng/ml or greater, Urology, 55, 694, 10.1016/S0090-4295(99)00585-3 Steuber, 2007, Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer, Clin Chem, 53, 233, 10.1373/clinchem.2006.074963 Nurmikko, 2000, Production and characterization of novel anti-prostate specific antigen (PSA) monoclonal antibodies that do not detect the internally cleaved Lys145-Lys146 inactive PSA, Clin Chem, 46, 1610, 10.1093/clinchem/46.10.1610 Nurmikko, 2001, Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate specific antigen lacking an internal cleavage site at Lys145-Lys146, Clin Chem, 47, 1415, 10.1093/clinchem/47.8.1415 Steuber, 2002, Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen, J Urol, 168, 1917, 10.1016/S0022-5347(05)64263-2 Linton, 2003, Benign prostate specific antigen (BPSA) in serum is increased in benign prostate disease, Clin Chem, 49, 253, 10.1373/49.2.253 Mikolajczyk, 2000, Seminal plasma contains “BPSA”, a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia, Prostate, 45, 271, 10.1002/1097-0045(20001101)45:3<271::AID-PROS11>3.0.CO;2-T Mikolajczyk, 2000, A precursor form of prostate specific antigen is highly elevated in prostate cancer compared with benign transitional zone prostate tissue, Cancer Res, 60, 756 Mikolajczyk, 1997, A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum, Urology, 50, 710, 10.1016/S0090-4295(97)00449-4 Mikolajczyk, 2001, A truncated precursor form of prostate specific antigen is a more specific serum marker of prostate cancer, Cancer Res, 61, 6958 Peter, 2001, Identification of precursor forms of free prostate specific antigen in serum of prostate cancer patients by immunosorption and spectrometry, Cancer Res, 61, 957 Mikolaiczyk, 2003, Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer, Keio J Med, 52, 86, 10.2302/kjm.52.86 Sokoll, 2002, Proenzyme PSA for the early detection of prostate cancer in the 2.5–4.0ng/ml total PSA range: preliminary analysis, Urology, 59, 261 Catalona, 2003, Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2.4–4ng/ml, J Urol, 170, 2181, 10.1097/01.ju.0000095460.12999.43 Clements, 1999, Molecular detection of prostate cells in ejaculate and urethral washings of men with suspected prostate cancer, J Urol, 161, 1337, 10.1016/S0022-5347(01)61680-X Muller, 2003, Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples, Urologe A, 42, 660 Harden, 2003, Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostatic adenocarcinoma, J Urol, 169, 1138, 10.1097/01.ju.0000049627.90307.4d Goessl, 2000, Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids, Cancer Res, 60, 5941 Goessl, 2001, DANN-based detection of prostate cancer in urine after prostatic massage, Urology, 58, 335, 10.1016/S0090-4295(01)01268-7 Chiou, 2003, Urinary 8 hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers, Clin Chim Acta, 334, 87, 10.1016/S0009-8981(03)00191-8 Bussemakers, 1999, DD3: a new prostate-specific gene, highly overexpressed in prostate cancer, Cancer Res, 59, 5975 Verhaegh, 2000, Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene, J Biol Chem, 275, 37496, 10.1074/jbc.M006293200 Schalken, 2003, New targets for therapy in prostate cancer: differential display code 3 (DD3 (PCA3)), a highly prostate cancer-specific gene, Urology, 62, 34, 10.1016/S0090-4295(03)00759-3 Hessels, 2003, (DD3 (PCA3))-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 44, 8, 10.1016/S0302-2838(03)00201-X de Kok, 2002, DD3 (PCA3), a very sensitive and specific marker to detect prostate tumours, Cancer Res, 62, 2695 Fradet, 2004, uPM3, a new molecular urine test for the detection of prostate cancer, Urology, 64, 311, 10.1016/j.urology.2004.03.052 Tinzl, 2003, uPM3 test. A new molecular assay detecting prostate cancer in urine samples; a new future perspective, AUA Program Abstr, 169, 121 Saad, 2003, Multicenter study of the uPM3 test, a new molecular urine assay to detect prostate cancer, AUA Program Abstr, 169, 121 Sommerfeld, 1996, Telomerase activity: a prevalent marker of malignant human prostate tissue, Cancer Res, 56, 218 Kallakury, 1997, Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas, Diagn Mol Pathol, 6, 192, 10.1097/00019606-199708000-00003 Meid, 2001, The use of telomerase activity for the detection of prostate cancer cells after prostatic massage, J Urol, 165, 1802, 10.1016/S0022-5347(05)66417-8 Vicentini, 2004, Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia, J Cancer Res Clin Oncol, 130, 217, 10.1007/s00432-003-0525-8 Botchkina, 2005, Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity, Clin Cancer Res, 11, 3243, 10.1158/1078-0432.CCR-04-1919 Wang, 2004, The expression and significance of surviving mRNA in urinary bladder carcinomas, J Cancer Res Clin Oncol, 130, 487, 10.1007/s00432-004-0561-z Lwaleed, 2000, Urinary tissue factor levels in patients with bladder and prostate cancer, Eur J Surg Oncol, 26, 44, 10.1053/ejso.1999.0739 Stoeber, 2002, Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments, J Natl Cancer Inst, 94, 1071, 10.1093/jnci/94.14.1071 Tanaka, 2003, Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers, Med Sci Monit, 9, MT61 Lombardo, 1997, Preliminary evaluation of 5a-reductase type 2 in urine as potential marker for prostate disease, Steroids, 62, 682, 10.1016/S0039-128X(97)00066-4